Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zishen Quyu Jiedu Granules is a Traditional Chinese Medicine (TCM) formula that has demonstrated clinical efficacy in the treatment of endometriosis (EMs). Research, including network pharmacology and in vivo experiments, suggests that its therapeutic effects are mediated through the modulation of various signaling pathways involved in oxidative stress and inflammation. The formula works by reducing inflammatory cell infiltration and decreasing levels of pro-inflammatory cytokines such as IL-6, IL-1β, and TNF-α. Concurrently, it enhances the body's antioxidant defense mechanisms by increasing the expression of NRF2, NQO1, and HO1, while decreasing KEAP1. This multi-component approach targets several key proteins and pathways to alleviate the symptoms and progression of endometriosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zishen Quyu Jiedu Granules.